Traditional ear tube surgery alternative developer AventaMed announced that it appointed U.S.-based Keith Jansen as its new president & CEO.
The Cork, Ireland-based medtech startup said in a news release that Jansen will succeed co-founder Olive O’Driscoll in the positions as he attempts to lead the company beyond its current startup phase and into the growth and commercialization phase, having already secured more than $6.2 million (€5.2 million) in funding.
Jansen previously held leadership roles at Boston Scientific, Cortek, InaVein and was president & CEO of Vascular Insights before his most recent position as senior VP of international business for the American Heart Association. O’Driscoll is set to assume an advisory consulting position and remain on the company’s board.
AventaMed develops the Solo Tympanostomy Tube Device (Solo TTD) for the quick and simple insertion of ear tubes without general anaesthesia, offering an alternative to the traditional surgical procedure that utilizes anaesthesia. The company had its primary patent granted with four more in the pipeline, obtained CE Mark approval for three of its products and is ready to begin clinical trials in the U.S. ahead of the pursuit of FDA clearance.
“I am so proud of what we’ve achieved to date in AventaMed, from spinning out of Cork Institute of Technology and becoming an Enterprise Ireland High Potential Start-Up to being commercially available and treating patients in Europe,” O’Driscoll said in the release. “I am excited to see where the future brings us as we expand into the U.S. Our succession team, headed up by Keith Jansen who is based in the US, will focus on the future commercial growth strategies. Manufacturing and other key functions will remain in Ireland where we anticipate additional commercial and high-tech positions becoming over the next two years.”